NCT02263352

Brief Summary

This study was performed to assess the efficacy of systemic lycopene (8 mgms Daily for two months) as an adjunct to scaling and root planing in chronic periodontitis patients with type 2 diabetes mellitus.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
40

participants targeted

Target at P25-P50 for phase_4

Timeline
Completed

Started Jan 2013

Shorter than P25 for phase_4

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2013

Completed
2 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2013

Completed
5 months until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2013

Completed
1.2 years until next milestone

First Submitted

Initial submission to the registry

October 1, 2014

Completed
12 days until next milestone

First Posted

Study publicly available on registry

October 13, 2014

Completed
Last Updated

October 13, 2014

Status Verified

October 1, 2014

Enrollment Period

2 months

First QC Date

October 1, 2014

Last Update Submit

October 8, 2014

Conditions

Keywords

Diabetes, Periodontitis, Oxidative stress, Antioxidant

Outcome Measures

Primary Outcomes (1)

  • Change in Serum MDA

    This unique outcome measure was assessed from baseline to 6 months post treatment by spectrophotometric estimation of serum Thiobarbituric acid substances (TBARS). The TBARS Assay measures malondialdehyde (MDA), a reactive compound formed from lipid peroxides that are generated under conditions of oxidative stress. Oxidative modification of lipids occurs with aging and various diseases, and increased oxidative stress is associated with diabetes and its complications. MDA forms an adduct with thiobarbituric acid (TBA). Results are calculated from a standard curve constructed with authentic MDA.

    6 Months Post treatment.

Secondary Outcomes (3)

  • Change in Modified Gingival Index

    6 Months post treatment.

  • Change in Probing pocket depth (PPD)

    6 Months post treatment.

  • Change in Clinical attachment level (CAL)

    6 Months post treatment.

Study Arms (2)

Lycored soft gels , Scaling and Rootplaning.

EXPERIMENTAL

Systemic Lycored soft gels,(Jagsonpal Pharma) was given orally 8mgms/day for 2 months and Scaling and rootplaning (otherwise known as conventional periodontal therapy, non-surgical periodontal therapy, or deep cleaning, is the process of removing or eliminating the etiologic agents - dental plaque, its products, and calculus) which was performed at baseline

Drug: Lycored soft gels Jagsonpal Pharma, Systemic 8mgms/dayDevice: Scaling and root planing

Scaling and Rootplaning only.

EXPERIMENTAL

Scaling and rootplaning(otherwise known as conventional periodontal therapy, non-surgical periodontal therapy, or deep cleaning, is the process of removing or eliminating the etiologic agents - dental plaque, its products, and calculus) which was performed at baseline.

Device: Scaling and root planing

Interventions

Lycopene 8mgms taken orally ,one per day for two months.

Also known as: rhodopurpurin,non-provitamin A carotenoid,
Lycored soft gels , Scaling and Rootplaning.

Scaling and root planing, otherwise known as conventional periodontal therapy, non-surgical periodontal therapy, or deep cleaning, is the process of removing or eliminating the etiologic agents - dental plaque, its products, and calculus

Also known as: Nonsurgical periodontal therapy, Conventional periodontal therapy.
Lycored soft gels , Scaling and Rootplaning.Scaling and Rootplaning only.

Eligibility Criteria

Age35 Years - 50 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • Type 2 diabetes
  • Patients on oral hypoglycemic drugs with no modification in therapy from the past 12 months
  • Chronic periodontitis as per AAP (American Academy of Periodontology) guidelines
  • Minimum of 15 natural teeth
  • At least four teeth with one or more sites with probing depth (PD) greater than or equal to 5 mm, clinical attachment level (CAL) greater than or equal to 4mm and bleeding on probing (BOP).

You may not qualify if:

  • History of antibiotic therapy within the previous 6 months
  • History of anti-inflammatory drugs within the previous 3 months
  • Pregnancy and lactation
  • Use of contraceptives or any other form of hormone
  • Usage of tobacco and tobacco related products
  • Periodontal treatment within 12 months.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Panineeya Mahavidhyalaya Institute of Dental Sciences and Research Centre

Hyderabad, 500060, India

Location

Related Publications (3)

  • Neyestani TR, Shariatzadeh N, Gharavi A, Kalayi A, Khalaji N. Physiological dose of lycopene suppressed oxidative stress and enhanced serum levels of immunoglobulin M in patients with Type 2 diabetes mellitus: a possible role in the prevention of long-term complications. J Endocrinol Invest. 2007 Nov;30(10):833-8. doi: 10.1007/BF03349224.

    PMID: 18075285BACKGROUND
  • Chandra RV, Prabhuji ML, Roopa DA, Ravirajan S, Kishore HC. Efficacy of lycopene in the treatment of gingivitis: a randomised, placebo-controlled clinical trial. Oral Health Prev Dent. 2007;5(4):327-36.

    PMID: 18173095BACKGROUND
  • Cohen DW, Friedman LA, Shapiro J, Kyle GC, Franklin S. Diabetes mellitus and periodontal disease: two-year longitudinal observations. I. J Periodontol. 1970 Dec;41(12):709-12. doi: 10.1902/jop.1970.41.12.709. No abstract available.

MeSH Terms

Conditions

Diabetes MellitusPeriodontitis

Interventions

Weights and MeasuresRoot Planing

Condition Hierarchy (Ancestors)

Glucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System DiseasesPeriodontal DiseasesMouth DiseasesStomatognathic Diseases

Intervention Hierarchy (Ancestors)

Investigative TechniquesDental ScalingDental ProphylaxisPeriodonticsDentistrySubgingival CurettagePreventive Dentistry

Study Officials

  • Dr.Manasa Ambati, MDS(Perio)

    Panineeya Mahavidhyalaya Institute of Dental Sciences and Research Centre,Road no:5,Kamala nagar,Dilsukhnagar,Hyderabad,India.

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Dr.Manasa Ambati

Study Record Dates

First Submitted

October 1, 2014

First Posted

October 13, 2014

Study Start

January 1, 2013

Primary Completion

March 1, 2013

Study Completion

August 1, 2013

Last Updated

October 13, 2014

Record last verified: 2014-10

Locations